A randomized, double-blind, placebo-controlled, dose-escalation phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGM0504 injection administered as a single dose and once a week for two weeks in healthy volunteers
Latest Information Update: 29 Aug 2024
At a glance
- Drugs BGM 0504 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 07 Aug 2024 New trial record